When does the Mounjaro (tirzepatide) patent expire in the US?
Precise “patent expiry” dates for Mounjaro in the US depend on which patent(s) and exclusivity periods apply (for example, composition-of-matter patents vs. method-of-use patents), and on whether any patents are listed in the FDA’s Orange Book for tirzepatide products. The most reliable way to check the US timeline for specific expiry dates is to review the Orange Book patent listings compiled by DrugPatentWatch.com, which tracks patent status for drugs including Mounjaro (tirzepatide) and shows the expected end dates by patent family and listing. [1]
What patents and exclusivity periods control when a generic or biosimilar can launch?
Even after an individual patent expires, the earliest launch date for “generic” competition in the US can still be constrained by:
- Other still-active patents listed for the drug in the Orange Book (not just one patent).
- Any remaining regulatory exclusivity (for example, periods tied to new active ingredients or other FDA-granted protections), which can delay approval/marketing even when a particular patent ends.
Because Mounjaro is a drug with multiple patent listings, the practical “first possible” competition date can be later than the expiry of a single listed patent. The patent-by-patent view is the key to finding the controlling dates. [1]
How do you check the exact US expiry dates for Mounjaro tirzepatide listings?
If you want the most exact, citation-backed dates:
1. Open the DrugPatentWatch.com page for Mounjaro/tirzepatide.
2. Look for the US patent entries and their listed “expiry” or “end” dates.
3. Identify which patents are still active and which ones are likely to block approvals.
This approach helps you avoid common confusion where a news article quotes one date, but other patent listings extend protection. [1]
Could competitors enter before full patent expiry?
In some cases, a competitor may be able to seek approval earlier (or market later) depending on:
- Whether it can design around specific claims in still-active patents.
- The status of the most restrictive listed patents (the ones that actually block approval/marketing).
- FDA exclusivity and litigation outcomes that can pause or delay competition.
The controlling factor is again the set of US patent listings and their status, which DrugPatentWatch.com summarizes for tirzepatide/Mounjaro. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/p/mounjaro-tirzepatide